跳至主要内容
临床试验/ITMCTR2023000060
ITMCTR2023000060尚未招募4 期

Clinical efficacy and safety trial of adding Tanreqing Injection for pediatric lobar pneumonia (sputum heat closed lung syndrome)

YANCHENG NO.1 PEOPLE'S HOSPITA0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 14(—)
性别
All

入选标准

  • (1) Inpatients who meet the Western medicine diagnostic criteria of Mycoplasma pneumoniae pneumonia in children presenting with lobar pneumonia;
  • (2) Meet the diagnostic criteria of TCM syndrome differentiation, phlegm, heat and closed lung syndrome;
  • (3) Between 2 and 14 years old, without gender limitation;
  • (4) The legal guardian understands and signs the informed consent form (children aged 10 years old and above who can understand and sign their own name should also sign it).

排除标准

  • (1) Patients with other respiratory diseases except mycoplasma pneumoniae pneumonia manifested by lobar pneumonia;
  • (2) Patients with severe primary diseases and mental diseases such as heart (congenital heart disease, myocarditis, etc.), liver (upper limit of AST and ALT), kidney (BUN, upper limit of Scr> normal value) and hematopoietic system (anemia above moderate degree);
  • (3) Serious abnormal blood oxygen saturation (<85%);
  • (4) People who are allergic to the recommended use of drugs;
  • (5) Children with acute infectious diseases such as measles and pertussis;
  • (6) Children with severe malnutrition and immunodeficiency;
  • (7) Patients who have participated in or are participating in the clinical trials of other drugs within the past one month;
  • (8) The investigator is not unsuitable for inclusion in the clinical trial.

研究者

发起方
YANCHENG NO.1 PEOPLE'S HOSPITA

相似试验